Pyxis Oncology (PYXS) to Acquire Apexigen (APGN) for $0 64/sh streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Pyxis Oncology to Acquire Apexigen Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate development Commercially and clinically validated APXiMAB. | May 24, 2023
You should read the following discussion and analysis of our financial condition
and results of operations together with our unaudited condensed consolidated
financial statements and related notes. | November 6, 2022
Pyxis Oncology’s IPO raised $168 million as the biotech steers toward the clinic with drug candidates and technology licensed from Pfizer. Theseus Pharma, IsoPlexis, and Cognition Therapeutics also went public; combined the four companies raised nearly half a billion dollars.